PubVisualPubVisual Book a Demo
Resources Blog About Contact Book a 30-Minute Demo →

Clinical Data Visualization in Pharma: What Works

A clean chart isn’t the goal, a chart a physician actually reads is.

The short version
  • It's easy to make trial data look good. Better typography, a consistent color system, a chart that would hold up in a design portfolio. None of it guarantees a physician understands it.
  • The visualizations that work lead with the comparison that matters, not every comparison the trial produced, and put the clinical meaning in words next to the numbers.
  • We build clinical data as a layered experience: the headline finding first, in plain terms, then the subgroup data and the statistical detail for whoever wants to go deeper.

A clean chart isn’t the goal, a chart a physician actually reads is. Here's what we found, and what it means for how you build your next story.

01Polished and understood are different things

It's easy to make trial data look good. Better typography, a consistent color system, a chart that would hold up in a design portfolio. None of that guarantees a physician understands what the data means for her patient, and that's the only outcome that counts.

Same finding, two shapesStatic page
The publication as published
The same finding, designed
One finding

Clinical Data Visualization in Pharma: What Works, told as a story a physician can finish.

The physician readerstill scanning the table…
0:38time to the point
Fig. 01The same approved finding, shown as a static page and as a designed story.

02What makes data readable under pressure

The visualizations that work lead with the comparison that matters, not every comparison the trial produced. They put the clinical meaning in words next to the numbers, instead of assuming the axis labels will do that work. A figure in a PDF shows the same depth to every physician, whether she's skimming for the topline number or double-checking the trial design.

“The physician who wants five seconds and the one who wants five minutes both get served by the same asset.”

03Letting physicians go as deep as they want

We build clinical data as a layered experience: the headline finding first, in plain terms, then the ability to tap into the subgroup data, the statistical detail, or a related endpoint, right from where she's standing. Nothing about the science changes. What changes is whether the physician who wants five seconds and the one who wants five minutes both get served by the same asset.

04Built for the review it has to survive

None of this adds review burden. Every figure still maps to the approved source, and one MLR review covers the interactive version end to end. The mapping and build work is ours to carry, not yours to invent from scratch.

The Impact Gap ReportFree · request access
Request the report →
Written by
The PubVisual Team
Editorial · PubVisual

We build the science communication our own field teams would want to use, then hand it to yours. This post came out of that same process.

More from the blog →
The Science of Engagement

Let her steer, from the same approved core

Smart Pathways turns trial data into a layered experience physicians can read at their own depth and pace.

Questions

Frequently asked questions

A chart can hold up in a design portfolio and still not tell a physician what the data means for her patient. The visualizations that work lead with the comparison that matters and put the clinical meaning in words next to the numbers.

By layering. The headline finding comes first, in plain terms, and the subgroup data, the statistical detail, and the related endpoints sit one tap below for whoever wants them.

No. Every figure still maps to the approved source, and one MLR review covers the interactive version end to end. The mapping and build work is ours to carry.